Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial. - Schreiber S; Sands BE; Danese S; Loftus EV Jr; Jeong AL; Kim DH; Lee YN; Colombel JF (Advances in therapy, 2026)